Michael Lübbert
Has participated in:
-
The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes
-
Epigenetic therapy of cancer : preclinical models and treatment approaches
-
MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum
-
The clinical value of decitabine monotherapy in patients with acute myeloid leukemia